APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Stroke
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
German APERIO® Hybrid Post- Market Clinical Follow-up Study APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke Study Type: prospective, multicenter, single-armed, open-label Participants: 13 participating centers in Germany p...
German APERIO® Hybrid Post- Market Clinical Follow-up Study APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke Study Type: prospective, multicenter, single-armed, open-label Participants: 13 participating centers in Germany planned PI: Dr. Christian Mathys, Evangelisches Krankenhaus Oldenburg, Germany Estimated Enrolment: 430 patients treated with APERIO® HYBRID Thrombectomy Device as a result of an acute stroke Follow up: 3 months Estimated Final Assessment: End of 2022
Tracking Information
- NCT #
- NCT04457479
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon